Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Net Margin (2016 - 2025)

Historic Net Margin for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to 13.47%.

  • Niagen Bioscience's Net Margin rose 61300.0% to 13.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.38%, marking a year-over-year increase of 147600.0%. This contributed to the annual value of 8.58% for FY2024, which is 144900.0% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Net Margin is 13.47%, which was up 61300.0% from 11.6% recorded in Q2 2025.
  • Niagen Bioscience's Net Margin's 5-year high stood at 24.65% during Q4 2024, with a 5-year trough of 51.17% in Q3 2021.
  • For the 5-year period, Niagen Bioscience's Net Margin averaged around 11.75%, with its median value being 6.88% (2022).
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -214400bps in 2021, then surged by 361200bps in 2023.
  • Over the past 5 years, Niagen Bioscience's Net Margin (Quarter) stood at 29.98% in 2021, then skyrocketed by 77bps to 6.88% in 2022, then surged by 108bps to 0.54% in 2023, then soared by 4483bps to 24.65% in 2024, then crashed by -45bps to 13.47% in 2025.
  • Its last three reported values are 13.47% in Q3 2025, 11.6% for Q2 2025, and 16.61% during Q1 2025.